Novo Nordisk Scores Hemophilia Win but Stumbles on Obesity Device as Buyback and India Launch Provid
Novo Nordisk’s stock has clawed back more than 40% from its March nadir, yet the Danish drugmaker’s latest…
Browsing Tag